Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) submitted its Monthly Return for the period ended 31 May 2026, confirming no changes in share capital, treasury shares or issued shares during the month.

Authorised / Registered Capital • Ordinary H shares: 260.30 million shares with a par value of RMB 1 each, unchanged from April. • Ordinary A shares (STAR Market): 766.39 million shares, also unchanged. • Aggregate registered capital remained at RMB 1.03 billion.

Issued and Treasury Shares • H shares in issue: 260.30 million; no treasury shares held. • A shares in issue: 765.58 million; treasury shares unchanged at 0.82 million. • No new shares were issued, cancelled or repurchased in either tranche during May.

Public Float Compliance Junshi Bio confirmed that its H-share free float remains above the 5 % minimum required for PRC issuers under Hong Kong Listing Rules.

Equity Incentive Schemes • H-Share Option Incentive Scheme (adopted 29 Sep 2025): 13.21 million options outstanding; no exercises or cancellations in May. The scheme still permits issuance of up to 64.23 million additional H shares subject to grant and vesting conditions. • A-Share Option Incentive Scheme (adopted 29 Sep 2025): 24.70 million options outstanding; no movement during the month. A maximum of 0.82 million A shares could be sourced from existing treasury shares upon exercise.

Other Instruments The company reported no warrants, convertible securities or other share-linked agreements outstanding or issued during the month.

Regulatory Confirmation Junshi Bio affirmed that all listing rule requirements were met, with no new funds raised in May and all public disclosures completed. The statement was signed by Joint Company Secretary Wang Zhengyu on 3 June 2026.